ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 982

A Novel Role for Nod2 in Controlling Autoantibody Production and Arthritis in SKG Mice

Ruth Napier1, Emily Vance 1, James O'Dell 2, Jill Poole 3, Bryant England 4, Michael Duryee 3, Ted Mikuls 2, Holly Rosenzweig 5 and Geoffrey Thiele 2, 1Oregon Health & Science University and Portland VA Hospital, Portland, OR, 2VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, NE, 3University of Nebraska Medical Center, Omaha, NE, 4VA Nebraska-Western IA Health Care System & University of Nebraska Medical Center, Omaha, 5Oregon Health & Science University and Portland VA Hospital, Oregon

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Animal models, autoantibodies, MAA, Nod2 and anti-CCP antibodies, rheumatoid arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 11, 2019

Title: RA – Animal Models Poster

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Rheumatoid arthritis (RA) is a systemic inflammatory disease that manifests in a chronic and debilitating polyarthritis. Although the etiology of RA is unknown pathogenic autoreactive T cells and autoantibodies including anti-CCP and anti- malondialdehyde-acetaldehyde (MAA) are thought to contribute to disease pathogenesis. Our recent studies identified the microbial sensor Nod2 as a critical genetic determinant in controlling the Th17-response and arthritis severity in SKG mice (Napier RJ et al. J Immunol 2018). However, whether Nod2 also contributes to autoantibody production in SKG mice is unknown. The purpose of this study was to extend our understanding of the protective mechanisms by which Nod2 controls arthritis in SKG mice to humoral immunity.

Methods: Balb/c, SKG and Nod2-/-SKG mice (6-8 wk age) were housed under specific pathogen-free conditions. Arthritis was induced by i.p. injection of 1.5 mg zymosan (Sigma-Aldrich) vs. saline (sham control). Serum IgG anti-CCP and anti-MAA antibodies were measured by ELISA 8 weeks later. Clinical arthritis for each paw was graded (0–4) in masked fashion. T cells (CD4+ and CD8+) were isolated from joint synovial fluid and evaluated (#T cells/ml) by flow cytometry.

Results: Nod2-/-SKG mice had significantly increased concentrations of serum anti-CCP and anti-MAA autoantibodies at 8 weeks post zymosan exposure compared to zymosan-exposed SKG (p = 0.0111 for CCP; and, p = 0.0223 for MAA) and sham treated Balb/c mice (p = 0.0371 for CCP; and, p = 0.0430 for MAA), the latter group demonstrating only negligible autoantibody reactivity. While there were increased concentrations of anti-CCP and anti-MAA antibodies in SKG mice exposed to zymosan compared to saline exposed Balb/c mice, they were not significantly higher (p = 0.080 for CCP; and, p = 0.111 for MAA). Comparisons with previously reported data (Napier et al.) showed serum anti-CCP and anti-MAA concentrations were increased in conjunction with arthritis scores in SKG and Nod2-/-SKG mice stimulated with zymosan. Likewise, we observed similar increases anti-CCP and anti-MAA concentrations that were associated with the total number of CD4+ T cells present in the synovial fluid collected from SKG and Nod2-/-SKG mice stimulated with zymosan.

Conclusion: These data suggest a previously unprecedented role for Nod2 in suppressing autoreactive B cell responses in the SKG arthritis model. Increased autoantibody concentrations correlated with increased synovial T cell responses and more severe arthritis. Understanding the mechanisms and consequences of enhanced autoantibody production in Nod2-deficient SKG mice will contribute to our understanding of the pathophysiology of RA. Moreover, arthritis resulting from Nod2 deficiency in SKG mice renders a disease model that is characterized by enhancements in both T cell responses and humoral immunity, suggesting that the Nod2-/-SKG mice might provide a highly relevant system for modeling RA.


MAA figure for ACR

Increased concentrations of serum anti-CCP and anti-MAA autoantibodies at 8 weeks post zymosan exposure in Nod2-/-SKG, zymosan-exposed SKG and saline treated Balb/c mice. IgG anti-MAA -A- and IgG anti-CCP -B- antibody concentrations were significantly elevated in Nod2-/-SKG zymosan treated mice as compared to SKG zymosan treated mice -p = 0.0111 for CCP; and, p = 0.0223 for MAA- and sham treated Balb/c mice -p = 0.0371 for CCP; and, p = 0.0430 for MAA-. No significant differences were observed in the concentrations of anti-CCP or anti-MAA antibodies between the SKG zymosan treated mice and the saline treated Balb/c mice.


Disclosure: R. Napier, None; E. Vance, None; J. O'Dell, None; J. Poole, None; B. England, None; M. Duryee, None; T. Mikuls, BMS, 2, Horizon, 2; H. Rosenzweig, None; G. Thiele, None.

To cite this abstract in AMA style:

Napier R, Vance E, O'Dell J, Poole J, England B, Duryee M, Mikuls T, Rosenzweig H, Thiele G. A Novel Role for Nod2 in Controlling Autoantibody Production and Arthritis in SKG Mice [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/a-novel-role-for-nod2-in-controlling-autoantibody-production-and-arthritis-in-skg-mice/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/a-novel-role-for-nod2-in-controlling-autoantibody-production-and-arthritis-in-skg-mice/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology